Literature DB >> 18583138

Synthesis and biological evaluation of new disubstituted analogues of 6-methoxy-3-(3',4',5'-trimethoxybenzoyl)-1H-indole (BPR0L075), as potential antivascular agents.

Nancy Ty1, Grégory Dupeyre, Guy G Chabot, Johanne Seguin, François Tillequin, Daniel Scherman, Sylvie Michel, Xavier Cachet.   

Abstract

6-Methoxy-3-(3',4',5'-trimethoxybenzoyl)-1H-indole (BPR0L075) (1) is a potent inhibitor of tubulin polymerization which exhibits both in vitro and in vivo activities against a broad spectrum of solid tumors. This compound was designed as a heterocyclic analogue of combretastatin A4 (CA-4), a natural stilbene derivative that disrupts the tumor vasculature and causes tumor regression. In the present work, we describe the design and synthesis of several new disubstituted analogues of 1, along with their biological evaluation as potential antivascular agents. Compound 13, bearing a hydroxyl group at the 7-position of the indole nucleus that mimics the hydroxyl group at the 3-position of the B-ring of CA-4, was identified as a potent inhibitor of tubulin polymerization and also as a cytotoxic agent against B16 melanoma cells at sub-micromolar concentration. In addition, compound 13 displayed marked morphological activity (rounding up) at nanomolar concentrations on endothelial cells (EA.hy 926 cells), which is indicative of potential antivascular activity. Interestingly, the corresponding 7-O-mesylate derivative 28 (an intermediate in the synthesis of 13), was also found active in cellular assays, although it was moderately active in the tubulin polymerization inhibition test. Finally, in order to better understand the SAR of disubstituted analogues of 1, two other position isomers (10 and 14), were synthesized and evaluated for their biological activities. It was noted that the 7-hydroxysubstituted analogue 13 was more potent than the 5-hydroxysubstituted analogue 10. In conclusion, this work has allowed the identification of biologically potent CA-4 analogues (13 and 28) and also contributes to a better understanding of the SAR of 1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18583138     DOI: 10.1016/j.bmc.2008.06.002

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  5 in total

1.  Synthesis and biological evaluation of indole-based, anti-cancer agents inspired by the vascular disrupting agent 2-(3'-hydroxy-4'-methoxyphenyl)-3-(3″,4″,5″-trimethoxybenzoyl)-6-methoxyindole (OXi8006).

Authors:  Matthew T Macdonough; Tracy E Strecker; Ernest Hamel; John J Hall; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem       Date:  2013-07-23       Impact factor: 3.641

2.  Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resembling combretastatin A-4 with application as a vascular disrupting agent.

Authors:  Mallinath B Hadimani; Matthew T Macdonough; Anjan Ghatak; Tracy E Strecker; Ramona Lopez; Madhavi Sriram; Benson L Nguyen; John J Hall; Raymond J Kessler; Anupama R Shirali; Li Liu; Charles M Garner; George R Pettit; Ernest Hamel; David J Chaplin; Ralph P Mason; Mary Lynn Trawick; Kevin G Pinney
Journal:  J Nat Prod       Date:  2013-09-09       Impact factor: 4.050

3.  Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.

Authors:  Bernard L Flynn; Gurmit S Gill; Damian W Grobelny; Jason H Chaplin; Dharam Paul; Annabell F Leske; Tina C Lavranos; David K Chalmers; Susan A Charman; Edmund Kostewicz; David M Shackleford; Julia Morizzi; Ernest Hamel; M Katherine Jung; Gabriel Kremmidiotis
Journal:  J Med Chem       Date:  2011-08-05       Impact factor: 7.446

4.  Synthesis and biological evaluation of isomeric methoxy substitutions on anti-cancer indolyl-pyridinyl-propenones: Effects on potency and mode of activity.

Authors:  Christopher J Trabbic; Sage M George; Evan M Alexander; Shengnan Du; Jennifer M Offenbacher; Emily J Crissman; Jean H Overmeyer; William A Maltese; Paul W Erhardt
Journal:  Eur J Med Chem       Date:  2016-06-13       Impact factor: 6.514

5.  Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors.

Authors:  Her-Shyong Shiah; Nai-Jung Chiang; Chia-Chi Lin; Chia-Jui Yen; Hui-Jen Tsai; Shang-Yin Wu; Wu-Chou Su; Kwang-Yu Chang; Ching-Chiung Wang; Jang-Yang Chang; Li-Tzong Chen
Journal:  Oncologist       Date:  2020-12-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.